Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Jefferies Group lowered their FY2019 earnings per share estimates for Supernus Pharmaceuticals in a research report issued on Monday. Jefferies Group analyst D. Steinberg now expects that the specialty pharmaceutical company will post earnings per share of $2.12 for the year, down from their prior estimate of $2.13. Jefferies Group has a “Buy” rating and a $51.00 price objective on the stock. Jefferies Group also issued estimates for Supernus Pharmaceuticals’ FY2020 earnings at $3.22 EPS and FY2021 earnings at $4.77 EPS.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The firm had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million.

TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/fy2019-earnings-forecast-for-supernus-pharmaceuticals-inc-issued-by-jefferies-group-supn.html.

Several other brokerages also recently issued reports on SUPN. Piper Jaffray Companies upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $30.00 to $44.00 in a report on Thursday, June 1st. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, May 11th. Cowen and Company increased their price target on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $48.43.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded down 1.619% during midday trading on Wednesday, reaching $41.025. The company’s stock had a trading volume of 208,812 shares. The company has a market cap of $2.07 billion, a price-to-earnings ratio of 20.709 and a beta of 1.31. Supernus Pharmaceuticals has a 12 month low of $17.25 and a 12 month high of $44.95. The stock has a 50-day moving average of $42.46 and a 200 day moving average of $33.49.

In other news, VP Padmanabh P. Bhatt sold 2,500 shares of the company’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the transaction, the vice president now directly owns 37,500 shares of the company’s stock, valued at $1,346,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the company’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $44.90, for a total value of $114,764.40. Following the transaction, the vice president now directly owns 24,944 shares of the company’s stock, valued at $1,119,985.60. The disclosure for this sale can be found here. Insiders have sold 24,291 shares of company stock valued at $962,766 over the last ninety days. 6.70% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. boosted its position in Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter valued at $127,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares during the period. Finally, Fortaleza Asset Management Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $160,000. 94.39% of the stock is owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.